Receive our newsletter – data, insights and analysis delivered to you
  1. Clinical Trials Analysis
March 2, 2021updated 09 Mar 2021 1:25pm

Asia-Pacific accounts for 45.3% share of global clinical trial activity in 2020

Asia-Pacific accounted for a 45.3% share of global clinical trials activity in 2020, an increase of 6.4% compared with a 38.9% average over the last ten-years, according to GlobalData.

In Asia-Pacific, single country studies held a 91.3% share for all clinical trials in 2020, compared with the ten-year average of 88.4%. Multinational trials accounted for an 8.7% share in 2020 against an average of 11.6% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in Asia-Pacific

Industry sponsored trials held a 49.9% share of all the clinical trials in Asia-Pacific in 2020, a rise over their ten-year average of 43.1%. Non-industry sponsored trials accounted for a 50.1% share in 2020, down from an average of 56.9% in the last ten years.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

2020 industry sponsored clinical trials in Asia-Pacific – Top therapy areas

Oncology was the leading therapy area for industry sponsored clinical trials in Asia-Pacific in 2020 with a 28.8% share, up from its ten-year average of 24.5%.

Infectious Disease held an 18.8% share in 2020, up from its ten-year average of 12.4%.

In the third place was Central Nervous System with an 11.3% share in 2020, down from its ten-year average of 12.8%. Respiratory recorded an 8.9% share in 2020, a rise over its ten-year average of 5.9%.

With a share of 8.6% in 2020, Cardiovascular witnessed a drop over its ten-year average of 10.3%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored clinical trials in Asia-Pacific by top therapy areas

Oncology was the leading therapy area for non-industry sponsored clinical trials in Asia-Pacific in 2020 with a 28.4% share, up from a ten-year average of 26.4%.

In the second place was Infectious Disease with an 18.9% share in 2020, which represented a rise over a ten-year average of 9.2%.

With a share of 17.4% in 2020, Central Nervous System witnessed a drop over its ten-year average of 19.1%. Respiratory held a 9.1% share in 2020, up against a ten-year average of 4.5%.

Cardiovascular held an 8.1% share, which was down from ten-year average of 10.8%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

2020 clinical trials in Asia-Pacific by phase

In terms of phases, Phase I trials led the industry sponsored clinical trials in Asia-Pacific in 2020, with a share of 41.0%, marking a rise over a ten-year average of 26.5%.

Phase II trials stood next with a 29.1% share in 2020, which was down against a ten-year average of 29.8%.

In the third place was Phase III trials with a 16.7% share in 2020, down from its ten-year average of 26.3%.

Phase IV trials held a 13.2% share in 2020, with a 4.2% drop over its ten-year average of 17.4%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

For non-industry sponsored clinical trials in Asia-Pacific, Phase II trials held a leading share of 41.0% in 2020, down from its ten-year average of 58.4%.

In the second place was Phase I trials that held a 23.5% share in 2020 and saw a 15% rise over a ten-year average of 8.5%.

Phase IV trials stood at a 22.2% share, even against a ten-year average of 22.4%.

Phase III trials held a 13.3% share in 2020, up from its ten-year average of 10.7%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU